{"id":"multihance-0-05-mmol-kg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gadolinium retention in tissues"},{"rate":"rare","effect":"Nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3932957","moleculeType":"Small molecule","molecularWeight":"459.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MultiHance contains gadobenate dimeglumine, a paramagnetic gadolinium chelate that distributes into the extracellular space and is taken up by hepatocytes. By altering local magnetic field homogeneity, it increases signal intensity in T1-weighted MRI images, improving visualization of tissue perfusion and lesion characterization. The agent is eliminated renally and hepatically.","oneSentence":"MultiHance is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:27.794Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"MRI contrast enhancement for central nervous system imaging"},{"name":"MRI contrast enhancement for body imaging including liver lesion characterization"}]},"trialDetails":[{"nctId":"NCT02633501","phase":"PHASE2","title":"P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Guerbet","startDate":"2016-06","conditions":"CNS Lesion, Blood Brain Barrier Defect","enrollment":312},{"nctId":"NCT03147989","phase":"","title":"Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2017-05-18","conditions":"Central Nervous System Diseases, Central Nervous System Neoplasms","enrollment":352},{"nctId":"NCT02070380","phase":"PHASE4","title":"Crossover Comparison of MultiHance and Dotarem","status":"COMPLETED","sponsor":"Bracco Diagnostics, Inc","startDate":"2014-02","conditions":"Brain Disease","enrollment":179},{"nctId":"NCT00937391","phase":"PHASE3","title":"Contrast-enhanced MRI in Children 2 Months to <2 Years","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Magnetic Resonance Imaging","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MultiHance 0.05 mmol/kg","genericName":"MultiHance 0.05 mmol/kg","companyName":"Bracco Diagnostics, Inc","companyId":"bracco-diagnostics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MultiHance is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the T1 relaxation time of water protons in tissues. Used for Contrast-enhanced MRI of the brain, spine, and associated tissues, Contrast-enhanced MRI of the liver, Contrast-enhanced MRI of the body (general use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}